VistaGen Therapeutics (NASDAQ:VTGN) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

VistaGen Therapeutics (NASDAQ:VTGN) posted its quarterly earnings results on Monday. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.03), FiscalAI reports. The company had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.40 million.

VistaGen Therapeutics Stock Down 0.6%

Shares of VTGN traded down $0.00 during mid-day trading on Monday, reaching $0.57. 1,020,450 shares of the stock traded hands, compared to its average volume of 895,989. The firm has a market cap of $22.70 million, a price-to-earnings ratio of -0.30 and a beta of 0.31. The stock has a fifty day simple moving average of $0.60 and a 200 day simple moving average of $1.03. VistaGen Therapeutics has a 12-month low of $0.43 and a 12-month high of $5.14.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Wednesday, June 3rd. Wall Street Zen lowered shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, VistaGen Therapeutics has an average rating of “Reduce” and a consensus target price of $0.95.

Institutional Trading of VistaGen Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in shares of VistaGen Therapeutics during the fourth quarter valued at approximately $25,000. Tudor Investment Corp ET AL purchased a new stake in shares of VistaGen Therapeutics during the fourth quarter valued at approximately $50,000. Millennium Management LLC raised its stake in shares of VistaGen Therapeutics by 853.0% during the fourth quarter. Millennium Management LLC now owns 197,045 shares of the company’s stock valued at $130,000 after purchasing an additional 176,369 shares during the period. Luminus Management LLC purchased a new stake in shares of VistaGen Therapeutics during the fourth quarter valued at approximately $232,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of VistaGen Therapeutics during the fourth quarter valued at approximately $68,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.